Sensus Healthcare
Market Cap
US$105.1m
Last Updated
2019/09/16 00:25 UTC
Data Sources
Company Financials +
Executive Summary
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide.
Snowflake
Fundamentals
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Sensus Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
NasdaqCM:SRTS
-0.9%
US Medical Equipment
1.3%
US Market
1 Year Return
-6.3%
NasdaqCM:SRTS
9.1%
US Medical Equipment
2.0%
US Market
SRTS underperformed the Medical Equipment industry which returned 8.7% over the past year.
SRTS underperformed the Market in United States of America which returned 1.7% over the past year.
Share holder returns
| SRTS | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | -0.9% | 1.3% |
| 30 Day | 0.2% | 0.7% | 3.9% |
| 90 Day | 19.7% | 4.4% | 3.4% |
| 1 Year | -6.3%-6.3% | 10.0%9.1% | 4.2%2.0% |
| 3 Year | 1.9%1.9% | 70.7%65.5% | 47.2%37.6% |
| 5 Year | n/a | 130.7%104.3% | 60.5%42.9% |
Price Volatility Vs. Market
How volatile is Sensus Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Is Sensus Healthcare, Inc. (NASDAQ:SRTS) Potentially Underrated?1 month ago | Simply Wall St
Is Sensus Healthcare, Inc.'s (NASDAQ:SRTS) CEO Pay Justified?2 months ago | Simply Wall St
If You Had Bought Sensus Healthcare (NASDAQ:SRTS) Stock A Year Ago, You'd Be Sitting On A 26% Loss, TodayValuation
Is Sensus Healthcare undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Sensus Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
Sensus Healthcare's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Sensus Healthcare is loss making, we can't compare its value to the US Medical Equipment industry average.
Sensus Healthcare is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Sensus Healthcare, we can't assess if its growth is good value.
Price Based on Value of Assets
Sensus Healthcare is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Sensus Healthcare expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
120.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Sensus Healthcare's revenue is expected to grow significantly at over 20% yearly.
Sensus Healthcare's earnings are expected to grow significantly at over 20% yearly.
Sensus Healthcare's revenue growth is expected to exceed the United States of America market average.
Sensus Healthcare's earnings growth is expected to exceed the United States of America market average.
Sensus Healthcare's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Sensus Healthcare will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Sensus Healthcare performed over the past 5 years?
-14.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Sensus Healthcare does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Sensus Healthcare's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Sensus Healthcare's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Sensus Healthcare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Sensus Healthcare has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Sensus Healthcare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Sensus Healthcare's financial position?
Financial Position Analysis
Sensus Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sensus Healthcare's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Sensus Healthcare's level of debt (0%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (6.2% vs 0% today).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are -1.4796746811792E+17x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Sensus Healthcare has sufficient cash runway for more than 3 years based on current free cash flow.
Unable to confirm if Sensus Healthcare has at least 1 year of cash runway based on growing free cash flows without relevant data.
Next Steps
Dividend
What is Sensus Healthcare's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Sensus Healthcare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Sensus Healthcare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Sensus Healthcare has not reported any payouts.
Unable to verify if Sensus Healthcare's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Sensus Healthcare has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Sensus Healthcare's salary, the management and board of directors tenure and is there insider trading?
9.3yrs
Average management tenure
CEO
Joe Sardano (66yo)
9.3yrs
Tenure
US$538,392
Compensation
Mr. Joseph C. Sardano, also known as Joe, has been the Chairman of the Board, Chief Executive Officer and President of Sensus Healthcare, Inc. since June 2010. Mr. Sardano, A recognized leader in the heal ...
CEO Compensation Analysis
Joe's remuneration is about average for companies of similar size in United States of America.
Joe's compensation has increased whilst company is loss making.
Management Age and Tenure
9.3yrs
Average Tenure
61yo
Average Age
The average tenure for the Sensus Healthcare management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
7.6yrs
Average Tenure
70yo
Average Age
The tenure for the Sensus Healthcare board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Clay Cockerell (62yo)
Medical Director & Member of Medical Advisory Board
- Tenure: 0yrs
Joe Sardano (66yo)
Chairman
- Tenure: 9.3yrs
- Compensation: US$538.39k
Arthur Levine (61yo)
Chief Financial Officer
- Tenure: 5.1yrs
- Compensation: US$584.60k
Kal Fishman (48yo)
COO & Chief Technology Officer
- Tenure: 9.3yrs
- Compensation: US$361.74k
Richard Golin (65yo)
Executive Vice President of International Sales
- Tenure: 9.3yrs
Steve Cohen (59yo)
Executive Vice President of Strategic Initiatives & Dermatology Sales
- Tenure: 9.3yrs
- Compensation: US$478.62k
Mark Nestor
Clinical Director & Member of Medical Advisory Board
- Tenure: 6.1yrs
Michael Sardano (30yo)
VP, General Counsel
- Tenure: 2.7yrs
Board Members
Clay Cockerell (62yo)
Medical Director & Member of Medical Advisory Board
- Tenure: 0yrs
Joe Sardano (66yo)
Chairman
- Tenure: 9.3yrs
- Compensation: US$538.39k
Armand Cognetta
Chairman of Medical Advisory Board
- Tenure: 8.6yrs
John Heinrich (71yo)
Independent Director
- Tenure: 7.6yrs
- Compensation: US$171.00k
Sam O'Rear (70yo)
Independent Director
- Tenure: 7.6yrs
- Compensation: US$171.00k
Gary Monheit
Member of Medical Advisory Board
- Tenure: 0yrs
Angela Abbatecola
Member of Medical Advisory Board
- Tenure: 0yrs
Mark Nestor
Clinical Director & Member of Medical Advisory Board
- Tenure: 6.1yrs
Bill McCall (72yo)
Independent Non-Executive Director
- Tenure: 3.9yrs
- Compensation: US$171.00k
William Roth
Member of Medical Advisory Board
- Tenure: 0yrs
Company Information
Sensus Healthcare, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sensus Healthcare, Inc.
- Ticker: SRTS
- Exchange: NasdaqCM
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$105.086m
- Shares outstanding: 16.50m
- Website: https://www.sensushealthcare.com
Number of Employees
Location
- Sensus Healthcare, Inc.
- 851 Broken Sound Parkway NW
- Suite 215
- Boca Raton
- Florida
- 33487
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRTS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 2016 |
Biography
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that p ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/16 00:25 |
| End of Day Share Price | 2019/09/13 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.